TY - JOUR
T1 - What happens when people discontinue taking medications? Lessons from COMBINE
AU - in collaboration with the ACTIVE group
AU - Stout, Robert L.
AU - Braciszewski, Jordan M.
AU - Subbaraman, Meenakshi Sabina
AU - Kranzler, Henry R.
AU - O'Malley, Stephanie S.
AU - Falk, Daniel
AU - Anton, Raymond
AU - Bain, Earle
AU - Canuso, Carla
AU - de Somer, Marc
AU - Dennehy, Ellen
AU - Graham, Jay
AU - Kosten, Thomas
AU - Mann, Karl
AU - McCann, David
AU - Meulien, Didier
AU - Meyer, Roger
AU - O'Brien, Charles
AU - Palumbo, Joseph
AU - Permutt, Thomas
AU - Rendenbach-Mueller, Beatrice
AU - Robinson, Rebecca
AU - Silverman, Bernard
AU - Torup, Lars
AU - Van Meter, Susan
AU - Winchell, Celia
AU - Wong, Conrad
N1 - Publisher Copyright:
© 2014 Society for the Study of Addiction.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Aims: We use intensive longitudinal data methods to illuminate processes affecting patients' drinking in relation to the discontinuation of medications within an alcohol treatment study. Although previous work has focused on broad measures of medication adherence, we focus on dynamic changes in drinking both before and after patients discontinue. Design: We conducted secondary data analyses using the COMBINE (Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence) study, focused on participants who discontinued medications prior to the planned end of treatment. Using an interrupted time-series analysis, we analysed drinking in the weeks before and after discontinuation and also studied outcomes at the end of the COMBINE follow-up. Setting: Unites States of America. Participants: We describe the subsample of COMBINE participants who discontinued medications (n=450), and compare them with those who were medication-adherent (n=559) and with those who discontinued but had substantial missing data (n=217). Measurements: The primary outcomes were percentage of days abstinent (PDA) and percentage of heavy drinking days (PHDD). Medication adherence data were used to approximate the date of discontinuation. Findings: For many patients, an increase in drinking began weeks before discontinuation (PDA: F(1,4803)=19.07, P<0.001; PHDD: F(1,4804)=8.58, P=0.003) then escalated at discontinuation (PDA: F(1,446)=5.05, P=0.025; PHDD: F(1,446)=4.52, P=0.034). Among other effects, the amount of change was moderated by the reason for discontinuation (e.g. adverse event; PDA: F(2,4803)=3.85, P=0.021; PHDD: F(2,4804)=5.36, P=0.005) and also whether it occurred in the first or second half of treatment (PDA: F(1,4803)=5.23, P=0.022; PHDD: F(1,4804)=8.79, P=0.003). Conclusions: A patient's decision to stop taking medications during alcohol treatment appears to take place during a weeks-long process of disengagement from treatment. Patients who discontinue medications early in treatment or without medical consultation appear to drink more frequently and more heavily.
AB - Aims: We use intensive longitudinal data methods to illuminate processes affecting patients' drinking in relation to the discontinuation of medications within an alcohol treatment study. Although previous work has focused on broad measures of medication adherence, we focus on dynamic changes in drinking both before and after patients discontinue. Design: We conducted secondary data analyses using the COMBINE (Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence) study, focused on participants who discontinued medications prior to the planned end of treatment. Using an interrupted time-series analysis, we analysed drinking in the weeks before and after discontinuation and also studied outcomes at the end of the COMBINE follow-up. Setting: Unites States of America. Participants: We describe the subsample of COMBINE participants who discontinued medications (n=450), and compare them with those who were medication-adherent (n=559) and with those who discontinued but had substantial missing data (n=217). Measurements: The primary outcomes were percentage of days abstinent (PDA) and percentage of heavy drinking days (PHDD). Medication adherence data were used to approximate the date of discontinuation. Findings: For many patients, an increase in drinking began weeks before discontinuation (PDA: F(1,4803)=19.07, P<0.001; PHDD: F(1,4804)=8.58, P=0.003) then escalated at discontinuation (PDA: F(1,446)=5.05, P=0.025; PHDD: F(1,446)=4.52, P=0.034). Among other effects, the amount of change was moderated by the reason for discontinuation (e.g. adverse event; PDA: F(2,4803)=3.85, P=0.021; PHDD: F(2,4804)=5.36, P=0.005) and also whether it occurred in the first or second half of treatment (PDA: F(1,4803)=5.23, P=0.022; PHDD: F(1,4804)=8.79, P=0.003). Conclusions: A patient's decision to stop taking medications during alcohol treatment appears to take place during a weeks-long process of disengagement from treatment. Patients who discontinue medications early in treatment or without medical consultation appear to drink more frequently and more heavily.
KW - Alcohol treatment outcome
KW - Clinical intervention
KW - Imputation
KW - Medication compliance
KW - Medication study
KW - Missing data
KW - Research methods
KW - Statistics
UR - http://www.scopus.com/inward/record.url?scp=84920381853&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920381853&partnerID=8YFLogxK
U2 - 10.1111/add.12700
DO - 10.1111/add.12700
M3 - Article
C2 - 25098969
AN - SCOPUS:84920381853
SN - 0965-2140
VL - 109
SP - 2044
EP - 2052
JO - Addiction
JF - Addiction
IS - 12
ER -